Clinical trials: II-IIIB Stages
Non-small Cell Lung Cancer
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with…
- Trial name
- NCT03285321
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Greg Durm, MD
Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as irinotecan, cisplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00616785
- Testing
- cisplatin, etoposide, irinotecan hydrochloride
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Yonsei University
Carcinoma, Non-Small-Cell Lung
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)
The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.
- Trial name
- NCT00979576
- Testing
- BIBF 1120 M + Pemetrexed, BIBF 1120 H + Pemetrexed, BIBF 1120 RD + Pemetrexed
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Obesity
Soy-Based Meal Replacement in Helping Women With Stage I, Stage II, or Stage III Breast Cancer in Complete Remission Lose Weight
RATIONALE: A diet using a soy-based meal replacement may help survivors of breast cancer lose weight and improve their quality of life.
- Trial name
- NCT00343434
- Testing
- behavioral dietary intervention, exercise intervention, soy isoflavones
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00769470
- Testing
- trastuzumab, carboplatin, docetaxel
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- Translational Oncology Research International
Non-small Cell Lung Cancer
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
To assess the efficacy and safety of Almonertinib versus placebo in patients with epidermal growth factor receptor mutation-positive (EGFRm+) stage II-IIIB non-small cell lung cancer (NSCLC), following complete tumor resection…
- Trial name
- NCT04687241
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
BRAF V600E Negative, KRAS Gene Mutation Negative
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab) works for the treatment of patients with colorectal cancer that cannot be removed by surgery (unresectable), has spread to nearby tissue or…
- Conditions
- BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT04117945
- Testing
- Cetuximab, Irinotecan, Panitumumab
- Where
- 15 sites in United States
- Volunteers
- 22 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer, Gestational Trophoblastic Tumor
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side…
- Conditions
- Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma
- Trial name
- NCT00004157
- Testing
- filgrastim, recombinant interleukin-11
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004092
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- City of Hope Medical Center
Lung Cancer
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00970684
- Testing
- bevacizumab, docetaxel, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Nathan Pennell, MD, PhD
Advanced Melanoma, Metastatic Melanoma
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable).
- Conditions
- Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01134614
- Testing
- Ipilimumab, Sargramostim
- Where
- 257 sites in United States
- Volunteers
- 245 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00834678
- Testing
- bendamustine, erlotinib, Maintenance erlotinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00265759
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 622 people
- Sponsor
- Alliance for Clinical Trials in Oncology
NSCLC, Stage I, II, IIIA, IIIB, Surgery
Pronostic and Predictive Value of EMT in Localized Lung Cancer
The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC.
- Conditions
- NSCLC, Stage I, II, IIIA, IIIB, Surgery, Progression, Epithelial Mesenchymal Transition
- Trial name
- TWISTlung (NCT03509779)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- European Georges Pompidou Hospital
Non Small Cell Lung Cancer Metastatic
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
BOOSTER is a randomised, controlled, phase II trial comparing osimertinib and bevacizumab versus osimertinib alone as second-line treatment in patients with stage IIIb-IVb non-small cell lung carcinoma (NSCLC) harbouring…
- Trial name
- BOOSTER (NCT03133546)
- Testing
- Osimertinib, Bevacizumab
- Where
- 25 sites in Ireland, Netherlands and 4 more
- Volunteers
- 155 people
- Sponsor
- ETOP IBCSG Partners Foundation
Carcinoma, Non-Small-Cell Lung
Phase II Iressa & Carbo/Gem in NSCLC
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
- Trial name
- NCT00264498
- Testing
- Gefitinib, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Lung Cancer
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00660816
- Testing
- erlotinib hydrochloride, pemetrexed disodium, docetaxel
- Where
- 13 sites in United States
- Volunteers
- 46 people
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
ARID1A and/or KDM6A Mutation and CXCL13 Expression
This phase II trial studies the effect of nivolumab in urothelial cancer that has spread to other places in the body (metastatic), specifically in patients with aberrations in ARID1A gene (ARID1A mutation) and correlate with…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT04953104
- Testing
- Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC
To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for resectable NSCLC patients.
- Conditions
- Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB
- Trial name
- NCT04699721
- Testing
- Probiotics (BiFico)+nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Xiangya Hospital of Central South University